The use of mesenchymal stromal cells in the treatment of coronavirus disease 2019
Abstract More than seven months into the coronavirus disease -19 (COVID-19) pandemic, infection from the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has led to over 21.2 million cases and resulted in over 760,000 deaths worldwide so far. As a result, COVID-19 has changed all our liv...
Main Authors: | Maurice A. Canham, John D. M. Campbell, Joanne C. Mountford |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-09-01
|
Series: | Journal of Translational Medicine |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12967-020-02532-4 |
Similar Items
-
Is there a place for mesenchymal stromal cell-based therapies in the therapeutic armamentarium against COVID-19?
by: Kátia Nunes da Silva, et al.
Published: (2021-07-01) -
Allogenic mesenchymal stromal cells and their extracellular vesicles in COVID-19 induced ARDS: a randomized controlled trial
by: Morteza Zarrabi, et al.
Published: (2023-06-01) -
Therapeutic potential of mesenchymal stem cells and their exosomes in severe novel coronavirus disease 2019 (COVID-19) cases
by: Atsunori Tsuchiya, et al.
Published: (2020-06-01) -
Bone Marrow-Derived Mesenchymal Stromal Cell Therapy in Severe COVID-19: Preliminary Results of a Phase I/II Clinical Trial
by: Céline Grégoire, et al.
Published: (2022-07-01) -
Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series
by: Seyed-Mohammad Reza Hashemian, et al.
Published: (2021-01-01)